Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Arcturus Therapeutics Holdings' Capital Expenditures history spans 8 years, with the latest figure at -$88000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to -$88000.0; the TTM value through Dec 2025 reached $230000.0, down 64.51%, while the annual FY2025 figure was $230000.0, 64.51% down from the prior year.
  • Capital Expenditures reached -$88000.0 in Q4 2025 per ARCT's latest filing, down from $181000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.5 million in Q4 2023 to a low of -$3.3 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $244722.2, with a median of $159000.0 recorded in 2025.
  • Peak YoY movement for Capital Expenditures: tumbled 420.66% in 2021, then skyrocketed 786.97% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at -$2.2 million in 2021, then plummeted by 49.71% to -$3.3 million in 2022, then soared by 174.27% to $2.5 million in 2023, then plummeted by 96.78% to $80000.0 in 2024, then crashed by 210.0% to -$88000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Capital Expenditures are -$88000.0 (Q4 2025), $181000.0 (Q3 2025), and $137000.0 (Q1 2025).